BioDelivery Sciences International, Inc. (BDSI)

Oncology Corporate Profile

Stock Performance

1.9000
0.0000

HQ Location

801 Corporate Center Drive, Suite 210
Raleigh, NC 27607

Company Description

BioDelivery Sciences International is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics. BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and oncology supportive care. BDSI's pain franchise currently consists of two products utilizing the patented BEMA technology. ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, and the E.U. (where it will be marketed as BREAKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer .The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and South Korea (licensed to Kunwha Pharmaceutical Co.). Additional product candidates are being developed utilizing the BEMA technology for conditions such as nausea/vomiting (BEMA Granisetron).

Website: http://www.bdsi.com/

Brand Generic Indication
ONSOLIS??fentanyl buccal soluble filmONSOLIS is an opioid analgesic indicated only for the management of breakthrough pain in patients with cancer, 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for

their underlying persistent cancer pain.

View additional information on commercial products here »

  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
BEMA_ BuprenorphineMu opioid receptor agonistCancer painIII
BEMA_ Granisetron5-HT3 receptor antagonistSupportive CareI

View additional information on product candidates here »

Source


http://www.bdsi.com/

Recent News Headlines

BioDelivery reports 4Q loss

3/17/2017 10:04 am

BioDelivery reports 4Q loss

3/17/2017 10:04 am

BioDelivery Sciences Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results

3/17/2017 10:03 am

[PR Newswire] - RALEIGH, N.C., March 17, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) today reported financial results for the fourth quarter and full year ended December 31, 2016, and provided ...

BioDelivery Sciences Announces Three Data Presentations on BELBUCA® at the American Academy of Pain Medicine 33rd Annual Meeting

3/16/2017 01:02 pm

[PR Newswire] - RALEIGH, N.C., March 16, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced three data presentations from research surrounding BELBUCA ® (buprenorphine) buccal film ...

BioDelivery Sciences to Host Conference Call and Webcast Reporting Fourth Quarter and Full-Year 2016 Financial Results on Friday, March 17

3/9/2017 12:00 pm

[PR Newswire] - RALEIGH, N.C., March 9, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it will report its fourth quarter and full-year 2016 financial results and host a conference ...

BioDelivery Sciences to Present at the 29th Annual ROTH Conference

3/8/2017 12:00 pm

[PR Newswire] - RALEIGH, N.C., March 8, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at the 29 th Annual ...

BioDelivery Sciences Secures Debt Financing with CRG

2/23/2017 12:03 pm

[PR Newswire] - RALEIGH, N.C., Feb. 23, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced today that it has entered into a senior credit facility with affiliates of CRG LP, a healthcare-focused ...

BioDelivery Sciences to Hold Analyst and Investor Day to Discuss BELBUCA® Commercialization Plans on February 1st in New York City

1/26/2017 08:02 pm

[PR Newswire] - RALEIGH, N.C., Jan. 26, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) will host an event for analysts and investors from 12:00 PM – 2:30 PM Eastern Time on Wednesday, February ...

MonoSol Rx Files Patent Infringement Suit against BioDelivery Sciences International (BDSI)

1/13/2017 08:03 pm

[GlobeNewswire] - WARREN, N.J., Jan. 13, 2017-- MonoSol Rx, a specialty pharmaceutical company utilizing its PharmFilm ® drug delivery technology to improve patient outcomes and to address unmet needs, today filed a patent ...